Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials

Currently viewing trials
(Last updated: December 06, 2019)

Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
Close
Treatment

BRCA1/2

Chemotherapy

Hormone Therapy

Radiation Oncology

Surgery

Surgery: Reconstruction

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Alternative Medicine

Decision Support

Diagnosing Breast Cancer

Genetics/Family History

Having Children

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Preventing Breast Cancer

Preventing Recurrence

Screening

Support/Education

Surveys/Interviews/Registries

1

NEAREST SITE: 650 miles
Mayo Clinic
Phoenix,AZ

VISITS: Number of visits unavailable

PHASE: I-II

NCT ID: NCT03409458

PT-112 plus Avelumab for Advanced Breast Cancer

A Phase 1b/2a Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab Scientific Title

Purpose
To compare the safety and effects (good and bad) of using the experimental drug PT-112 and the immunotherapy drug avelumab (Bavencio®) to treat metastatic breast cancer.
Who is this for?
Women and men with metastatic (stage IV) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PT-112, by IV </li> <li class="seamTextUnorderedListItem">Avelumab (Bavencio®)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule.</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PT-112 is an experimental drug that works like both a chemotherapy and an immunotherapy. </li> <li class="seamTextUnorderedListItem">Avelumab (Bavencio®) is a type of immunotherapy drug called a PD-L1 inhibitor. It is currently approved to treat Merkel cell and bladder cancer and its use in breast cancer is considered experimental.</li> <li class="seamTextUnorderedListItem">Patients with metastatic breast cancer are eligible for only the phase I (dose-finding) part of this study.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03409458' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.2519' target='_blank'>Journal of Clinical Oncology: A phase I study of PT-112 in advanced solid tumors</a> </li><li class='seamTextUnorderedListItem'><a href='http://phosplatin.com/about/' target='_blank'>Phosplatin Therapeutics: A New Generation of Cancer Therapies</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.uh.edu/nsm/chemistry/news-events/stories/2014/1023-cancer-drug.php' target='_blank'>University of Houston: Clinical Trials of Anti-Cancer Drug PT-112 Begin in U.S.</a> </li></ul>
See more